Supplementary Figure 2D from A Phase Ib/II Study of Ramucirumab in Combination with Emibetuzumab in Patients with Advanced Cancer
Year: 2023
Type: supplementary-materials
Abstract: Progression-free Survival in NSCLC population, MET +23
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4361887577
